Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. (Previously presented) A method of treating an individual comprising administration of a composition comprising cord blood or cord blood-derived stem cells, wherein said administration delivers at least 1×10^{10} total nucleated cells, or at least 1×10^{9} stem cells, to an individual in need of said administration.

2. (Previously presented) The method of claim 1 wherein the cord blood or cord blood-derived stem cells are suitable for bone marrow transplantation.

3. (Original) The method of claim 2 wherein the cord blood or cord blood-derived stem cells are suitable for administration in humans.

4. (Previously presented) The method of claim 2 wherein a plurality of the cord blood-derived stem cells express the cell surface markers $CD34^{+}$ and $CD38^{-}$.

5. (Original) The method of claim 2 wherein a plurality of the umbilical cord blood stem cells express the cell surface markers CD34+ and CD38+.

6. (Previously presented) The method of claim 2 additionally comprising contacting the cord blood or cord blood-derived stem cells with a growth factor.

7. (Original) The method of claim 6 wherein the growth factor is a cytokine, lymphokine, interferon, colony stimulating factor (CSF), interferon, chemokine, interleukin, human hematopoietic growth factor, hematopoietic growth factor ligand, stem cell factor, thrombopoietin (Tpo), granulocyte colony-stimulating factor (G-CSF), leukemia inhibitory factor, basic fibroblast growth factor, placenta derived growth factor or epidermal growth factor.

8. (Previously presented) The method of claim 6 wherein the cord blood or cord blood-derived stem cells are contacted with the growth factor to induce differentiation into a plurality of cell types.

9. (Previously presented) The method of claim 6 wherein the cord blood or cord blood-derived stem cells are contacted treated with the growth factor to prevent or suppress differentiation into a particular cell type.

10. (Original) A method of treating myelodysplasia which comprises administering cord blood or cord blood-derived stem cells to a patient in need thereof.

11. (Previously presented) The method of claim 1 wherein said administration delivers at least 3×10^{10} total nucleated cells or at least 3×10^{9} stem cells.

12. (Canceled)

13. (Previously presented) The method of claim 1 wherein said administration delivers at least 2 x 10^{10} total nucleated cells or at least 2 x 10^{9} stem cells.

14. (Previously presented) The method of claim 1 wherein said individual has a disease, disorder or condition that includes an inflammation component.

15. (Previously presented) The method of claim 1 wherein said individual has a vascular disease, disorder or condition.

16. (Original) The method of claim 15 wherein said disease, disorder or condition is atherosclerosis.

17. (Previously presented) The method of claim 1 wherein said individual has a neurological disease, disorder or condition.

18. (Previously presented) The method of claim 17, wherein said disease, disorder or condition is selected from the group consisting of amyotrophic lateral sclerosis and multiple sclerosis.

19. (Canceled).

20. (Canceled)

21. (Previously presented) The method of claim 1, wherein said individual has undergone a trauma or injury.

22. (Original) The method of claim 21, where said trauma or injury is trauma or injury to the central nervous system.

23. (Original) The method of claim 21, wherein said trauma or injury is trauma or injury to the peripheral nervous system.

24. (Previously presented) The method of claim 1, wherein said at least 1 x 10^{10} total nucleated cells, or at least 1 x 10^{9} stem cells, comprises cells derived from a plurality of donors.

25. (Original) The method of claim 1 wherein none of said cells in said composition is HLA-typed prior to said administration.

26. (Original) The method of claim 1 wherein said composition is preconditioned for between 18 hours and 21 days prior to said administration.

27. (Original) The method of claim 1 wherein said composition is preconditioned for between 48 hours and 10 days prior to said administration.

28. (Original) The method of claim 1, wherein said composition is preconditioned for between 3-5 days prior to said administration.